[go: up one dir, main page]

PE20141370A1 - Inhibidores de quinasa - Google Patents

Inhibidores de quinasa

Info

Publication number
PE20141370A1
PE20141370A1 PE2014000923A PE2014000923A PE20141370A1 PE 20141370 A1 PE20141370 A1 PE 20141370A1 PE 2014000923 A PE2014000923 A PE 2014000923A PE 2014000923 A PE2014000923 A PE 2014000923A PE 20141370 A1 PE20141370 A1 PE 20141370A1
Authority
PE
Peru
Prior art keywords
alkyl
formula
iloxi
pirazol
triazolo
Prior art date
Application number
PE2014000923A
Other languages
English (en)
Inventor
Niel Monique Bodil Van
Nicholas Charles Ray
Lilian Alcaraz
Terry Aaron Panchal
Andrew Stephen Robert Jennings
Elisabetta Armani
Andrew Peter Cridland
Christopher Hurley
Original Assignee
Chiesi Farma Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47471708&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20141370(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiesi Farma Spa filed Critical Chiesi Farma Spa
Publication of PE20141370A1 publication Critical patent/PE20141370A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/02—Formic acid
    • C07C53/06—Salts thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/40—Acylated on said nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA (I) DONDE W ES N U O, DONDE N ESTA SUSTITUIDO CON H, ALQUILO(C1-C6) O CICLOALQUILO(C3-C5); Y ES -OC(O)-, -OC(O)NH-, ENTRE OTROS; R1 ES UN GRUPO DE FORMULA (IIa), (IIb), ENTRE OTROS, EN DONDE R8 Y R9 SON CADA UNO H, ALQUILO(C1-C6), ENTRE OTROS; R10 ES H, CN, ENTRE OTROS; R12 ES H, ALQUILO(C1-C6) O HALOGENO; X1 ES C, N, CH O NH; R2 ES UN GRUPO DE FORMULA (IIIa), ENTRE OTROS, EN DONDE R14 ES F, CH3, C2H5, CH2OH, ENTRE OTROS; R15 Y R16 SON CADA UNO CH3 O C2H5; A ES CICLOALQUILENO(C5-C7) FUSIONADO A FENILO O HETEROARILO DE 5 O 6 MIEMBROS. SON COMPUESTOS PREFERIDOS: 1-[5-TERT-BUTIL-2-(2-MORFOLIN-4-IL-ETIL)-2H-PIRAZOL-3-IL]-3-{(1S,4R)-4-[3-((S)-2-METIL-PIPERIDIN-1-IL)-[1,2,4]TRIAZOLO[4,3-a]PIRIDIN-6-ILOXI]-1,2,3,4-TETRAHIDRO-NAFTALEN-1-IL}-UREA; 1-{5-TERT-BUTIL-2-[1-(2-DIMETILAMINO-ETIL)-1H-IMIDAZOL-4-IL]-2H-PIRAZOL-3-IL}-3-[(1S,4R)-4-(3-PIPERIDIN-1-IL-[1,2,4]TRIAZOLO[4,3-a]PIRIDIN-6-ILOXI)-1,2,3,4-TETRAHIDRO-NAFTALEN-1-IL]-UREA; ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LAS QUINASAS ACTIVADAS POR MITOGENO p38 MAPK SIENDO UTILES EN EL TRATAMIENTO DE ASMA
PE2014000923A 2011-12-09 2012-12-05 Inhibidores de quinasa PE20141370A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11192871 2011-12-09
EP12187931 2012-10-10

Publications (1)

Publication Number Publication Date
PE20141370A1 true PE20141370A1 (es) 2014-10-17

Family

ID=47471708

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2014000923A PE20141370A1 (es) 2011-12-09 2012-12-05 Inhibidores de quinasa

Country Status (34)

Country Link
US (5) US8907094B2 (es)
EP (1) EP2788349B1 (es)
JP (1) JP6128449B2 (es)
KR (1) KR101994381B1 (es)
CN (3) CN105968110B (es)
AR (1) AR089189A1 (es)
AU (1) AU2012347350C1 (es)
BR (1) BR112014013760A2 (es)
CA (1) CA2858447C (es)
CL (1) CL2014001486A1 (es)
CO (1) CO6970602A2 (es)
CY (1) CY1118340T1 (es)
DK (1) DK2788349T3 (es)
EA (1) EA025268B1 (es)
ES (1) ES2612259T3 (es)
GE (1) GEP201706735B (es)
HR (1) HRP20161714T1 (es)
HU (1) HUE029826T2 (es)
IL (1) IL232958A (es)
LT (1) LT2788349T (es)
ME (1) ME02624B (es)
MX (1) MX359200B (es)
MY (1) MY170656A (es)
PE (1) PE20141370A1 (es)
PH (1) PH12014501277B1 (es)
PL (1) PL2788349T3 (es)
PT (1) PT2788349T (es)
RS (1) RS55602B1 (es)
SG (1) SG11201402985VA (es)
SI (1) SI2788349T1 (es)
TW (1) TWI618703B (es)
UA (1) UA115320C2 (es)
WO (1) WO2013083604A1 (es)
ZA (1) ZA201404156B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140103925A (ko) * 2011-12-09 2014-08-27 키에시 파르마슈티시 엣스. 피. 에이. 4-히드록시-1,2,3,4-테트라히드로나프탈렌-1-일 우레아 및 호흡기 질환의 치료에서의 이들의 용도
SG10201604656YA (en) * 2011-12-09 2016-07-28 Chiesi Farma Spa Kinase inhibitors
DK2788349T3 (en) * 2011-12-09 2017-01-30 Chiesi Farm Spa kinase inhibitors
GB201214750D0 (en) 2012-08-17 2012-10-03 Respivert Ltd Compounds
WO2014033449A1 (en) 2012-08-29 2014-03-06 Respivert Limited Kinase inhibitors
WO2014033446A1 (en) 2012-08-29 2014-03-06 Respivert Limited Kinase inhibitors
EP2890695A2 (en) 2012-08-29 2015-07-08 Respivert Limited Kinase inhibitors
WO2014076484A1 (en) 2012-11-16 2014-05-22 Respivert Limited Kinase inhibitors
US20160016934A1 (en) 2013-03-14 2016-01-21 Respivert Limited Kinase inhibitors
KR102283876B1 (ko) 2013-04-02 2021-07-29 옥슬러 액퀴지션즈 리미티드 키나제 저해제로서 유용한 우레아 유도체
WO2014162121A1 (en) 2013-04-02 2014-10-09 Topivert Pharma Limited Kinase inhibitors based upon n-alkyl pyrazoles
WO2014195402A1 (en) 2013-06-06 2014-12-11 Chiesi Farmaceutici S.P.A. Kinase inhibitors
RU2015151834A (ru) * 2013-06-06 2017-06-08 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Ингибиторы киназы
KR20160016973A (ko) 2013-06-06 2016-02-15 키에시 파르마슈티시 엣스. 피. 에이. P38 - map 키나아제 억제제로서 [1, 2, 4] 트리아졸로 [4, 3 - a] 피리딘의 유도체
EP2818471A1 (en) * 2013-06-27 2014-12-31 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Nitrogen bicyclic compounds as inhibitors for Scyl1 and Grk5
CN113717162A (zh) 2013-12-20 2021-11-30 奥苏拉收购有限公司 用作激酶抑制剂的脲衍生物
JP6630280B2 (ja) 2014-02-14 2020-01-15 レスピバート・リミテツド 抗炎症化合物としての芳香族複素環化合物
MA40775A (fr) 2014-10-01 2017-08-08 Respivert Ltd Dérivé d'acide 4-(4-(4-phényluréido-naphtalén -1-yl) oxy-pyridin-2-yl) amino-benzoïque utilisé en tant qu'inhibiteur de la kinase p38
US10206949B2 (en) 2015-09-21 2019-02-19 Ofer Agam Composition that relieves heartburn, GERD and hangovers
AR107165A1 (es) 2015-12-23 2018-03-28 Chiesi Farm Spa Inhibidores de quinasa
WO2017108736A1 (en) 2015-12-23 2017-06-29 Chiesi Farmaceutici S.P.A. N-[3-(3-{4-[[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl} -ureido)-phenyl]-methanesulfonamide derivatives and their use as p38 mapk inhibitors
AR107164A1 (es) 2015-12-23 2018-03-28 Chiesi Farm Spa INHIBIDORES DE QUINASA p38
BR112018067552A2 (pt) 2016-04-06 2019-01-08 Topivert Pharma Ltd inibidores de cinase
US10364245B2 (en) * 2017-06-07 2019-07-30 Chiesi Farmaceutici S.P.A. Kinase inhibitors
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
JP7012152B2 (ja) 2017-10-05 2022-02-10 フルクラム セラピューティクス，インコーポレイテッド Ｆｓｈｄの治療のためにｄｕｘ４および下流遺伝子発現を低減するｐ３８キナーゼ阻害剤
CN108424372B (zh) * 2018-05-11 2021-08-10 浙江华贝药业有限责任公司 2，2，2-三氟-n-[(s)-4-羰基四氢萘-1-基]-乙酰胺的纯化工艺
CN108707086B (zh) * 2018-05-15 2021-08-10 浙江华贝药业有限责任公司 一种(1s，4s)-n-（4-羟基四氢萘-1-基）叔丁氧基碳酰胺的纯化工艺
AR116628A1 (es) 2018-10-18 2021-05-26 Syngenta Crop Protection Ag Compuestos microbiocidas
CN115209736A (zh) 2020-03-05 2022-10-18 先正达农作物保护股份公司 杀真菌组合物
CN112174870B (zh) * 2020-10-12 2023-07-21 蔡霈 (r)-1-烷烃酰基-2-取代吡咯烷-2-甲酰胺的制备方法及其药用用途

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU650953B2 (en) 1991-03-21 1994-07-07 Novartis Ag Inhaler
US5756533A (en) 1995-03-10 1998-05-26 G.D. Searle & Co. Amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors
US6034057A (en) 1995-07-06 2000-03-07 Zeneca Limited Peptide inhibitors of fibronectine
US6248713B1 (en) 1995-07-11 2001-06-19 Biogen, Inc. Cell adhesion inhibitors
YU25500A (sh) 1999-05-11 2003-08-29 Pfizer Products Inc. Postupak za sintezu analoga nukleozida
GB0028383D0 (en) 2000-11-21 2001-01-03 Novartis Ag Organic compounds
EP1241176A1 (en) 2001-03-16 2002-09-18 Pfizer Products Inc. Purine derivatives for the treatment of ischemia
EP1381592A1 (en) * 2001-04-13 2004-01-21 Boehringer Ingelheim Pharmaceuticals Inc. 1,4-disubstituted benzo-fused compounds
EP1458682B1 (en) 2001-12-20 2006-08-30 Bayer HealthCare AG 1,4-dihydro-1,4-diphenylpyridine derivatives
AU2003257991A1 (en) * 2002-08-08 2004-02-25 Boehringer Ingelheim Pharmaceuticals, Inc. Fluorinated phenyl-naphthalenyl-urea compounds as inhibitors of cytokines involved in inflammatory processes
JP2006517580A (ja) * 2003-02-14 2006-07-27 ファイザー・プロダクツ・インク 抗炎症化合物としてのトリアゾロピリジン
SE0302487D0 (sv) 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
CA2564355C (en) * 2004-05-07 2012-07-03 Amgen Inc. Protein kinase modulators and method of use
EP1609789A1 (en) 2004-06-23 2005-12-28 Eli Lilly And Company Ureido-pyrazole derivatives and their use as kinase inhibitors
ATE400567T1 (de) 2004-06-23 2008-07-15 Lilly Co Eli Kinaseinhibitoren
JP4084836B2 (ja) 2004-08-12 2008-04-30 ファイザー・インク ｐ３８ＭＡＰキナーゼインヒビターとしてのトリアゾロピリジニルスルファニル誘導体
GB0418015D0 (en) * 2004-08-12 2004-09-15 Pfizer Ltd New compounds
WO2006018727A2 (en) 2004-08-18 2006-02-23 Pharmacia & Upjohn Company Llc Triazolopyridine compounds useful for the treatment of inflammation
GB0502258D0 (en) 2005-02-03 2005-03-09 Argenta Discovery Ltd Compounds and their use
CA2610509A1 (en) 2005-06-03 2006-12-14 Bayer Healthcare Ag 1-methyl-1h-pyrazole-4-carboxamides useful as cancer chemotherapeutic agents
WO2007091152A1 (en) * 2006-02-09 2007-08-16 Pfizer Limited Triazolopyridine compounds
CN101146029B (zh) * 2006-09-13 2011-12-28 华为技术有限公司 一种分组重排序方法和系统
US8188113B2 (en) 2006-09-14 2012-05-29 Deciphera Pharmaceuticals, Inc. Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
AR063141A1 (es) 2006-10-04 2008-12-30 Pharmacopeia Inc Derivados de 2- ( benzimidazolil ) purina 8- sustituida para inmunosupresion
US7790741B2 (en) 2006-10-06 2010-09-07 Abbott Laboratories Imidazothiazoles and imidazoxazoles
CN101636397B (zh) 2007-04-13 2012-06-13 中国人民解放军军事医学科学院毒物药物研究所 脲类化合物、其制备方法及其医药用途
US8202899B2 (en) 2007-07-25 2012-06-19 Array Biopharma Inc. Pyrazole urea derivatives used as kinase inhibitors
CA2695636A1 (en) 2007-08-10 2009-02-19 Astellas Pharma Inc. Bicyclic acylguanidine derivative
TWI496779B (zh) 2008-08-19 2015-08-21 Array Biopharma Inc 作為ｐｉｍ激酶抑制劑之三唑吡啶化合物
WO2010068258A1 (en) 2008-12-08 2010-06-17 Cgi Pharmaceuticals, Inc. Imidazopyrazine syk inhibitors
JP2012511563A (ja) * 2008-12-11 2012-05-24 レスピバート・リミテツド ｐ３８ＭＡＰキナーゼ阻害剤
JP5583694B2 (ja) 2009-01-05 2014-09-03 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｂ２受容体を調節するピロリジン化合物
CA2752693A1 (en) * 2009-02-17 2010-08-26 Chiesi Farmaceutici S.P.A. Triazolopyridine derivatives as p38 map kinase inhibitors
WO2010108058A2 (en) 2009-03-20 2010-09-23 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Small molecule inhibitors of dusp6 and uses therefor
US8721380B2 (en) 2009-08-12 2014-05-13 Konica Minolta Holdings, Inc. Method for manufacturing display panel
EP2308866A1 (de) 2009-10-09 2011-04-13 Bayer CropScience AG Phenylpyri(mi)dinylpyrazole und ihre Verwendung als Fungizide
GB0921731D0 (en) 2009-12-11 2010-01-27 Respivert Ltd Theraputic uses
GB201005589D0 (en) * 2010-04-01 2010-05-19 Respivert Ltd Novel compounds
WO2011124930A1 (en) * 2010-04-08 2011-10-13 Respivert Limited P38 map kinase inhibitors
GB201009731D0 (en) * 2010-06-10 2010-07-21 Pulmagen Therapeutics Inflamma Kinase inhibitors
DK2788349T3 (en) 2011-12-09 2017-01-30 Chiesi Farm Spa kinase inhibitors
KR20140103925A (ko) 2011-12-09 2014-08-27 키에시 파르마슈티시 엣스. 피. 에이. 4-히드록시-1,2,3,4-테트라히드로나프탈렌-1-일 우레아 및 호흡기 질환의 치료에서의 이들의 용도
SG10201604656YA (en) 2011-12-09 2016-07-28 Chiesi Farma Spa Kinase inhibitors
KR20160016973A (ko) 2013-06-06 2016-02-15 키에시 파르마슈티시 엣스. 피. 에이. P38 - map 키나아제 억제제로서 [1, 2, 4] 트리아졸로 [4, 3 - a] 피리딘의 유도체
WO2014195402A1 (en) 2013-06-06 2014-12-11 Chiesi Farmaceutici S.P.A. Kinase inhibitors
RU2015151834A (ru) 2013-06-06 2017-06-08 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Ингибиторы киназы

Also Published As

Publication number Publication date
CN105968110A (zh) 2016-09-28
US9315503B2 (en) 2016-04-19
ES2612259T3 (es) 2017-05-16
PL2788349T3 (pl) 2017-04-28
US8907094B2 (en) 2014-12-09
UA115320C2 (uk) 2017-10-25
CN104039787B (zh) 2016-06-29
SI2788349T1 (sl) 2017-01-31
CO6970602A2 (es) 2014-06-13
CA2858447A1 (en) 2013-06-13
KR101994381B1 (ko) 2019-06-28
IL232958A (en) 2017-08-31
CN105968110B (zh) 2018-04-27
LT2788349T (lt) 2016-12-27
US20150344475A1 (en) 2015-12-03
MX359200B (es) 2018-09-19
NZ625965A (en) 2016-08-26
EP2788349B1 (en) 2016-10-26
HUE029826T2 (en) 2017-04-28
SG11201402985VA (en) 2014-08-28
EP2788349A1 (en) 2014-10-15
EA025268B1 (ru) 2016-12-30
TWI618703B (zh) 2018-03-21
PH12014501277A1 (en) 2014-09-08
US20130150343A1 (en) 2013-06-13
PT2788349T (pt) 2017-02-02
WO2013083604A1 (en) 2013-06-13
EA201490949A1 (ru) 2014-11-28
US20140323470A1 (en) 2014-10-30
MX2014006724A (es) 2014-08-29
AU2012347350C1 (en) 2017-01-19
ME02624B (me) 2017-06-20
JP2015500260A (ja) 2015-01-05
HRP20161714T1 (hr) 2017-02-10
ZA201404156B (en) 2016-07-27
US9527846B2 (en) 2016-12-27
CY1118340T1 (el) 2017-06-28
US20150080375A1 (en) 2015-03-19
DK2788349T3 (en) 2017-01-30
IL232958A0 (en) 2014-08-03
RS55602B1 (sr) 2017-06-30
JP6128449B2 (ja) 2017-05-17
US9145413B2 (en) 2015-09-29
CN104039787A (zh) 2014-09-10
TW201336833A (zh) 2013-09-16
KR20140105516A (ko) 2014-09-01
GEP201706735B (en) 2017-09-25
CL2014001486A1 (es) 2014-11-14
PH12014501277B1 (en) 2014-09-08
CN105503861A (zh) 2016-04-20
AU2012347350A1 (en) 2014-07-03
BR112014013760A2 (pt) 2017-06-13
HK1200828A1 (en) 2015-08-14
HK1222647A1 (zh) 2017-07-07
CA2858447C (en) 2020-10-27
AR089189A1 (es) 2014-08-06
MY170656A (en) 2019-08-24
AU2012347350B2 (en) 2016-09-08
US20160229852A1 (en) 2016-08-11
US9139584B2 (en) 2015-09-22
CN105503861B (zh) 2017-08-01

Similar Documents

Publication Publication Date Title
PE20141370A1 (es) Inhibidores de quinasa
AR061844A1 (es) Pirimidil-ciclopentanos como inhibidores de protein-quinasa akt
PE20120224A1 (es) Derivados de 1h-imidazo-[4,5-c]-quinolinona
NO20073729L (no) Heterocykliske forbindelser som CCR2B-antagonister
AR073920A1 (es) Derivados urea de nortropanos sustituidos, medicamentos que contienen dichos compuestos , su uso en el tratamiento de enfermedades mediadas por la inhibicion de la enzima 11beta-hidroxiesteroide deshidrogenasa y proceso para su preparacion.
PE20060573A1 (es) Derivados de urea ciclicos sustituidos como inhibidores de proteinas quinasas
AR066492A1 (es) Derivados de imidazoquinolina, proceso para su preparacion, composiciones farmaceuticas que los contienen y usos para el tratamiento de enfermedades virales, bacterianas, alergicas y distintos tipos de canceres.
PE20090183A1 (es) Derivados de 1-oxa-3,9-diaza-espiro-[5.5]undecan-2-ona como moduladores de ccr5
AR046394A1 (es) Derivados de quinolinas y quinazolinas, metodo de preparacion de los mismos y composiciones farmaceuticas que los contienen.
AR071763A1 (es) Pirazoles trisustituidos, composiciones farmaceuticas que los contienen, y usos de los mismos en el tratamiento de trastornos neurologicos y psiquiatricos
AR076860A1 (es) Derivados de 7-aril- 1,2,4-triazolo[4,3-a]piridina moduladores alostericos positivos de receptores mglur2, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de trastornos neurologicos y siquiatricos.
PE20120321A1 (es) Indazoles sustituidos con oxazol como inhibidores de pi3-quinasa
AR046119A1 (es) Pirimidinas sustituidas con sulfoximina como inhibidores de cdk y / o vegf su preparacion y sus usos como medicamento
BRPI0410714B8 (pt) derivados de quinazolina macrocíclicos, seu processo de preparação, composição farmacêutica que os compreende e uso
AR074688A1 (es) Derivados de piridazinona, procedimiento para prepararlos, medicamentos que los contienen y uso de los mismos para el tratamiento de tumores.
PE20070004A1 (es) Imidazoquinolinas como inhibidores de quinasa de lipido
PE20091849A1 (es) Compuestos y composiciones como inhibidores de cinasa
PE20081341A1 (es) Inhibidores de la actividad de la akt
PE20061119A1 (es) PIRAZOLO PIRIDINAS SUSTITUIDAS COMO INHIBIDORES DE CINASAS FAK, KDR Y Tie
EA201070395A1 (ru) Ингибиторы polo-подобных киназ
PE20090773A1 (es) Derivados de morfolina pirimidina
AR083578A1 (es) INHIBIDORES DE N/N-LACTAMA ACETIL-CoA CARBOXILASA
NO20053794L (no) N-(1-benzyl-2-oxo-2-(1-piperazinyl) etyl)-1-piperidinkarboksamid-derivater og relaterte forbindelsers bruk som CGRP-antagonister for behandling av hodepine.
NI200600262A (es) 4-fenilamino-quinazolin-6-il-amidas.
AR070130A1 (es) Compuestos moduladores de beta-amiloide, un proceso para su obtencion, el uso del compuesto para la fabricacion de un medicamento y dicho medicamento

Legal Events

Date Code Title Description
FG Grant, registration